Skip to content
lifestyle.brownplanet.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
lifewellmd.com
UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights
August 6, 2026
UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103
July 15, 2026
UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution
June 2, 2026
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
May 15, 2026
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
May 13, 2026
UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights
May 7, 2026
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
March 30, 2026
LifeWellMD unveils 2026 men’s performance and longevity lab in Palm Beach and Port St. Lucie
March 12, 2026
Florida Physician Launches 2026 “Hardware and Software” Men’s Longevity Initiative Integrating PRP, Shockwave, Hormone Optimization, and Advanced Cellular Therapies
March 9, 2026
Harvard-Trained Oncologist Dr. Kumar Expands Acupuncture Support for Cancer Patients in Palm Beach
March 9, 2026